Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Bitcoin

Strategy’s Aggressive Bitcoin Acquisition Sparks Investor Concern

Robert Sasse by Robert Sasse
December 9, 2025
in Bitcoin, Crypto Stocks, Mergers & Acquisitions
0
Strategy Stock
0
SHARES
29
VIEWS
Share on FacebookShare on Twitter

Strategy Inc. has initiated its most significant Bitcoin purchasing spree in six months, acquiring a substantial 10,624 BTC between December 1st and 7th. The nearly $963 million expenditure was funded entirely through equity sales. While the company’s shares responded positively initially, climbing 2.6 percent to $183.69 on Monday, the financing method has raised significant red flags among market analysts.

Equity Sales Fuel Crypto Buying Binge

To finance this massive crypto acquisition, Strategy leveraged capital markets aggressively. The company raised $928 million from the sale of 5.13 million common shares, supplemented by an additional $35 million from preferred stock offerings. The average purchase price for Bitcoin was approximately $90,615 per coin.

This latest buying wave expands Strategy’s holdings to 660,624 BTC, representing over 3.1 percent of Bitcoin’s total possible supply of 21 million coins. The firm’s total cost basis for its entire portfolio stands at $49.35 billion, reflecting an average entry price of $74,696 per Bitcoin. With current prices hovering around $91,000, the company is sitting on an unrealized gain of roughly $11 billion.

Dilution Fears Trigger Analyst Downgrades

The decision to fund the purchase through share issuance is drawing sharp criticism. Analysts have swiftly adjusted their outlooks, citing heightened dilution risks for existing shareholders. TD Cowen reduced its price target from $535 to $500, explicitly pointing to these increasing dilution concerns. Cantor Fitzgerald issued an even more drastic revision, slashing its target from $560 to $229—a staggering 59 percent cut.

Should investors sell immediately? Or is it worth buying Strategy?

Despite a recent partial recovery, Strategy’s stock price remains more than 50 percent below its six-month highs. In a related move just one week prior to the Bitcoin purchase, the company established a $1.44 billion USD reserve. This fund is intended to cover dividend obligations on its preferred shares for a 21-month period, a signal that its cost of capital is rising.

Revised Forecasts and Technical Indicators

The volatile cryptocurrency market has forced Strategy to recalibrate its financial guidance for 2025. Following Bitcoin’s decline from a late-October peak of $111,612 to a November low beneath $81,000, the company revised its projections downward. Details of the updated target range were included in an SEC filing, highlighting Strategy’s ongoing dependence on Bitcoin’s price performance.

Technical indicators further illustrate the stock’s turbulent state. The Relative Strength Index (RSI) currently reads 84.2, signaling a technically overbought condition. Meanwhile, the annualized 30-day volatility sits at 60.66 percent, underscoring the extreme price swings characteristic of the asset. In pre-market trading on Tuesday, shares were quoted at $183.37.

Ad

Strategy Stock: Buy or Sell?! New Strategy Analysis from March 25 delivers the answer:

The latest Strategy figures speak for themselves: Urgent action needed for Strategy investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Strategy: Buy or sell? Read more here...

Tags: Strategy
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Coinbase Stock
Analysis

Regulatory Proposal Sparks Sell-Off in Coinbase Shares

March 25, 2026
Unitedhealth Stock
Analysis

UnitedHealth Faces Multifaceted Regulatory Scrutiny Ahead of Earnings

March 25, 2026
CyberArk Software Stock
Bonds

Palo Alto Networks Finalizes Debt Terms Following CyberArk Acquisition

March 24, 2026
Next Post
Healwell AI Stock

Healwell AI Shares Struggle to Gain Traction Despite Strong Revenue Growth

XRP Stock

Institutional Capital Pours Into XRP Amid Regulatory Milestones

Vita Coco Company Stock

The Vita Coco Company: Robust Earnings and a Favorable Trade Shift Fuel Rally

Recommended

Lockheed Martin Stock

Defense Giant Lockheed Martin Secures Billions in New Military Contracts

6 months ago
OKE stock news

Amalgamated Bank Increases Stake in CF Industries as Market Opinions Vary

3 years ago
IBM Stock

IBM’s AI Windfall Fails to Impress Stock Market

7 months ago
Blackstonecured Lending Fund Stock

Blackstone BDC Insider Purchase Defies Analyst Downgrades

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Figma Embraces Third-Party AI to Power Its Design Ecosystem

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

Evolent Health Bets on AI Leadership Amid Share Price Decline

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Trending

Gossamer Bio Stock
Analysis

Gossamer Bio’s Pivotal FDA Meeting Looms in June 2026

by Kennethcix
March 25, 2026
0

The future of Gossamer Bio hinges on a critical regulatory discussion scheduled for June 2026. The biopharmaceutical...

SOXX ETF Stock

Semiconductor Sector Faces Supply Chain Strain Amid Helium Shortage Concerns

March 25, 2026
Fair Isaac Stock

Regulatory Scrutiny and Price Wars Threaten Fair Isaac’s Dominance

March 25, 2026
Figma Stock

Figma Embraces Third-Party AI to Power Its Design Ecosystem

March 25, 2026
BioNano Genomics Stock

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Gossamer Bio’s Pivotal FDA Meeting Looms in June 2026
  • Semiconductor Sector Faces Supply Chain Strain Amid Helium Shortage Concerns
  • Regulatory Scrutiny and Price Wars Threaten Fair Isaac’s Dominance

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com